| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | -0.081 | 0.1 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | 0.073 | 0.1 |
| mRNA | AZD8055 | CTRPv2 | pan-cancer | AAC | -0.05 | 0.1 |
| mRNA | Vorinostat | gCSI | pan-cancer | AAC | 0.072 | 0.1 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | 0.075 | 0.1 |
| mRNA | dinaciclib | CTRPv2 | pan-cancer | AAC | 0.074 | 0.1 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.047 | 0.2 |
| mRNA | I-BET151 | CTRPv2 | pan-cancer | AAC | -0.043 | 0.2 |
| mRNA | BMS-536924 | CTRPv2 | pan-cancer | AAC | -0.049 | 0.2 |
| mRNA | TAE684 | CTRPv2 | pan-cancer | AAC | -0.048 | 0.2 |